Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

The Cigna Group

CI

HIGHLY FAVORABLE

May 22, 2026

Research Conclusion

BUY at ~$285. Cigna trades at 9.4x FY2026E adj EPS + 10% FCF yield — orphan multiple for a $200B revenue diversified PBM-payer post-MA divestiture. The market discounts: Anthem PBM contract renewal risk (2027), FTC "New Era" PBM regulation, CEO transition (Cordani → Evanko), and GLP-1 cost pressure. PWFV $355-378 (+25-33%); base case $389 (+36%); bear case $240 (-16%). The $10B+ buyback at 10% FCF yield mechanically accelerates per-share value.

Company Overview & Moat Assessment

The Cigna Group is a diversified managed care + PBM company with $200B+ revenue (FY2025). Post-divestiture of Medicare Advantage business (closed FY2024), now focused on two segments: Cigna Healthcare (Commercial Insurance, ~30% revenue, ~40% earnings) and Evernorth Health Services (Express Scripts PBM + specialty pharmacy, ~70% revenue). FCF ~$8B (FY2026E). CEO transition (David Cordani → Brian Evanko, CFO promotion) in progress.

▲ Bull Case

  • ◆Anthem renews + Evernorth gains share from "New Era" transparency: Anthem PBM contract renewed 2027; New Era 100% rebate pass-through attracts large self-insured employers; Evernorth grows 5-10% above market
  • ◆FCF recovers to $9-10B by FY2027; buyback compounds: Medicare run-out clears; interest cost normalization; $10B buyback at $285 retires 12% of float
  • ◆Multiple re-rates from 9.4x to 12-14x: Managed care peer mid-range; UNH 18x ceiling not required

▼ Bear Case

  • ◆Anthem insources PBM by 2027 (-$50B revenue): ELV competitive retaliation; CI scale advantage lost; Express Scripts goodwill impairment
  • ◆FTC "New Era" margin compression -$2B: Permanent rebate cap; PBM margin structural reset
  • ◆CEO Evanko strategic missteps: Less visionary than Cordani; client persuasion on New Era fails
Primary Debate on Wall Street

“Whether PBM regulatory overhang is structural (multiple stays 9x) or cyclical (re-rate to 12x). Anthem renewal is the binary catalyst.”

Top Catalysts
  • ◆Anthem PBM renewal (2026-2027) — THE catalyst
  • ◆FTC "New Era" rulemaking (ongoing) — margin impact quantified
  • ◆FY2026 EPS guidance (quarterly) — trajectory vs. $30.35 consensus
  • ◆FCF recovery pace (quarterly) — Medicare run-out completion
  • ◆Buyback execution (quarterly) — $2.5B+/Q pace
Top Risks
  • ◆Anthem insources PBM by 2027 (-$50B revenue) — HIGH impact if materialized
  • ◆FTC "New Era" margin cap — structural rebate compression -$2B
  • ◆GLP-1 cost surge — pharmaceutical cost pressure on specialty pharma
  • ◆CEO Evanko transition stumble — less visionary track record than Cordani
  • ◆Express Scripts goodwill impairment — $40B at risk if EBITDA declines

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/CI/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.